Awad MM et al. Acquired resistance to KRAS^G12C inhibition in cancer. N Engl J Med 2021;384(25):2382-93. Abstract

Dy GK et al. Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100. AACR 2022;Abstract CT008.

Jänne PA et al. Adagrasib in non-small-cell lung cancer harboring a KRAS^G12C mutation. N Engl J Med 2022;387(2):120-31. Abstract

Ostrem JM et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013;503(7477):548-51. Abstract

Sabari JK et al. Activity of adagrasib (MRTX849) in patients with KRAS^G12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial. ASCO 2022;Abstract LBA9009.

Skoulidis F et al. Sotorasib for lung cancer with KRASp.G12C mutation. N Engl J Med 2021;384(25):2371-81. Abstract

Spira AI et al. KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRAS^G12C mutation. ASCO 2022;Abstract 9002.

Yu HA et al. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Clin Oncol 2015;10(3):431-7. Abstract